Trump demands 17 pharma companies extend lowest global prices to U.S. within 60 days

---

Full Story

President Trump has issued a formal demand to 17 major pharmaceutical firms, calling for drug price reforms within 60 days. He warned that failure to comply will trigger aggressive action from the administration.

The letter outlines several specific requirements including extending most favored nation pricing to Medicaid. This pricing model requires firms to offer the lowest global prices to U.S. programs.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 24% | Right 36% | Center 32% | Unrated 8%

The Context

Companies are also instructed to apply these pricing standards to newly launched drugs. Trump is demanding that firms repatriate revenue gained from foreign markups to benefit American patients.

Direct purchasing at most favored nation rates is part of the administration’s plan to cut consumer costs. Officials argue this will lower drug prices without restricting access.

The President’s team, including Secretary Kennedy and Administrator Oz, has been tasked with enforcing the initiative. They are reportedly ready to act if firms do not comply.

Critics of the pharmaceutical industry claim that U.S. consumers pay more than any other nation for identical medications. Supporters of reform say global pricing disparities must be addressed.

Industry defenders argue that price controls may harm innovation and limit access to new treatments. They warn that strict mandates could affect R&D investment.

The administration’s move reflects growing public demand for lower prescription costs. Drug pricing has become a central issue in domestic health policy debates.